About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline
LOG IN
LOG IN

1 1 (May 25, 2021)

handle is hein.crs/govedkz0001 and id is 1 raw text is: Congressional *aResearch Service Drug Enforcement Administration Set to Increase Registered Marijuana Manufacturers for Research Purposes May 25, 2021 On May 14, 2021, the Drug Enforcement Administration (DEA) announced that it would soon register additional manufacturers to cultivate marijuana for research purposes. For over 50 years, the National Center for Natural Products Research at the University of Mississippi has been the only DEA-registered manufacturer of marijuana for research purposes, operating under a contract administered by the National Institute on Drug Abuse (NIDA). While marijuana is also cultivated in states that allow for its recreational and medical use, the federal government considers the University of Mississippi to be the only lawful source, as Schedule I controlled substances may only be manufactured for research purposes under the Controlled Substances Act (CSA), and manufacturers must register with the DEA Marijuana Supply for Researchers Under the CSA, marijuana and its derivatives are classified as Schedule I controlled substances, unless an exception applies. This means the manufacture (or cultivation), possession, and distribution of marijuana are illegal, except for the purpose of DEA-sanctioned research. DEA(as delegated by the Attorney General) is required to register an applicant who would like to manufacture Schedule I or II controlled substances if it determines that such registration is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA thus seeks to balance the demands from researchers for a larger, more diverse supply of marijuana against the United States' obligations under international treaties. Further, the supply of marijuana and other Schedule I and II controlled substances is subject to production quota limitations determined by DEA based on an annual assessment of need. In recent years, both Congress and the executive branch have acted to address marijuana supply issues. In 2015, the Improving Regulatory Transparency for New Medical Therapies Act (P.L. 114-89) amended the CSA and imposed deadlines on DEA to issue notice of each application for a registration to manufacture Schedule I substances for research and then act on the application. Congressional Research Service https://crsreports.congress.gov IN11682 CRS INSIGHT Prepared for Membersand Committeesof Congress

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline.

Purchase Access

Contact us for annual subscription options:

Contact Us

Already a HeinOnline Subscriber?

Log In

profiles profiles most